Screener
Amgen AMGN Net gains (losses) on investments
Net gains (losses) on investments at other companies
Other financials
Where this comes from
Reported directly by Amgen in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnInvestments.
The source filing: Amgen’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000318154-26-000126
| Line item | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Impairment of intangible assets | — | 800 |
| Stock-based compensation expense | 240 | 242 |
| Deferred income taxes | (467) | (672) |
| Loss (gain) on equity securities | 301 | (741) |
| Other items, net | 8 | (73) |
| Changes in operating assets and liabilities, net of acquisitions: | ||
| Trade receivables, net | (680) | (1,823) |
| Inventories | (13) | 527 |
Item 1. FINANCIAL STATEMENTS
FAQ
- What is Amgen's net gains (losses) on investments?
- Amgen (AMGN) reported net gains (losses) on investments of -$158M in Q2 2026.
- What does net gains (losses) on investments mean?
- Realized and unrealized gains/losses on investments removed from operating cash flow since they're investing-related.
Ask your AI about Amgen's net gains (losses) on investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude